Search for genetically stable bioengineered gut and liver tissue takes step forward

February 8, 2018, Cincinnati Children's Hospital Medical Center
Cultured two-dimensional human posterior gut endoderm cells (PGEC) that where genetically queued to drive the generation of three-dimensional hindgut spheroids and intestinal tissues. Scientists at the Cincinnati Children's Center for Stem Cell & Organoid Medicine and Yokohama City University publish data in Stem Cell Reports about a bioengineering strategy that uses induced pluripotent stem cells to generate PGECs. Researchers report they instructed the cells to form genetically stable gut and liver tissues that were of sufficient volume and size for viable transplant into patients. Credit: Cincinnati Children's

Before medical science can bioengineer human organs in a lab for therapeutic use, two remaining hurdles are ensuring genetic stability—so the organs are free from the risk of tumor growth—and producing organ tissues of sufficient volume and size for viable transplant into people.

Scientists from the Cincinnati Children's Center for Stem Cell and Organoid Medicine and Yokohama City University (YCU) in Japan report in Stem Cell Reports achieving both goals with a new production method for bioengineered human gut and tissues.

The researchers first used a multi-step process of genetic and biochemical manipulation that included the genes FGF, TGF and WNT, which transformed human induced (iPS) into CDX2-positive posterior gut endodermal (PGECs). The protocol is designed to mimic natural embryonic development, and CDX2 is a molecular marker found in gut tissues, according to Takanori Takebe, MD, lead investigator on the study and a physician at Cincinnati Children's and YCU.

Although PGECs are still at an embryonic development stage, they're already programmed to form the gastrointestinal (GI) tract. At this point, however, they aren't specifically queued genetically to form stomach, liver or intestine.

Next, study authors used additional series of progressive genetic and biochemical manipulations, telling PGECs to form human hindgut and liver organoids.

"Compared to gastrointestinal organoids and liver-generated directly from induced pluripotent stem , generation from PGECs resulted in robust and genetically stable formation of different tissue GI types, without causing benign tumors called teratomas," said first author Ran-Ran Zhang, PhD, a research fellow at Cincinnati Children's. "Our data also show liver organoids grown from PGECs and transplanted into immunodeficient mice with liver disease grew, functioned well and prevented liver failure."

Study data indicate about 20 percent of mice not receiving liver organoid transplants still survived for 30 days, compared to roughly 60 percent of the mice that received transplants.

Building a Better Organ

Induced pluripotent stem cells (iPS) start out as adult cells, like mature skin cells. They are genetically and biochemically reprogrammed to act like . IPS cells have the potential to become any cell type in the human body. This makes them an indispensable research tool for studying human disease and lab-grown human tissues of specific organ systems, such as the GI tract.

But iPS cells and organ tissues grown directly from them are prone to genetic variations and chromosome instability, bringing the possibility of tumor formation. This hurdle to using organ tissues grown directly from iPS cells for applications requires a different approach, said Takebe and his co-authors.

Human organoids have been generated in past studies with progenitor cells, such as the posterior gut endoderm progenitors generated in this study. Research data indicate the progenitor cells are more genetically stable than iPS cells. But previous studies that bioengineered organoids from progenitor cells included the use animal byproducts (reagents and other substances). This makes the resulting organoids unsafe for therapeutic use in people, according to researchers.

In this study, researchers avoid the use of animal byproducts throughout the entire bioengineering process. This includes the initial programming of iPS cells and then their subsequent queuing to become posterior gut endoderm cells.

The Importance of Size

Current bioengineering technologies can safely grow human liver tissues to model and study the progression of specific diseases—such as fatty liver disease—and test for drugs that can treat them. But for lab-generated liver organoids, and other gastrointestinal organoids like intestine, therapeutic viability in patients requires the be highly reproducible and able to grow large enough. They also must function well enough treat or cure medical conditions.

The quantity of PEGC-derived liver organoid tissues in the current study was sufficient for mouse transplant. They also demonstrated the ability to produce highly functional hepatic cells that allowed the mini-livers to filter toxins from the body, the organ's primary role. This is demonstrated in part by the significantly improved survival rate of laboratory mice transplanted with the liver organoids.

PGEC-derived organoids also demonstrated extensive potential for expansion and elongation. In laboratory cell culture plates, feeder-free PEGCs generated by the researchers multiplied their numbers by 1021 after being re-plated 20 times—-demonstrating their mass production potential.

Following this study, researchers continue refining the bioengineering process, with emphasis on liver organoids. In collaboration with Japan's National Centers for Child Health and Development, the research team is preparing for a clinical trial to transplant a bioengineered liver into a patient, Takebe said.

Explore further: Scientists create successful mass production system for bioengineered livers

More information: Stem Cell Reports (2018). DOI: 10.1016/j.stemcr.2018.01.006

Related Stories

Scientists create successful mass production system for bioengineered livers

December 5, 2017
Researchers report creating a biologically accurate mass-production platform that overcomes major barriers to bioengineering human liver tissues suitable for therapeutic transplant into people.

Patient-derived organoids may help personalize the treatment of gastrointestinal cancers

January 17, 2018
A new BJS (British Journal of Surgery) review highlights the potential of 3D organoid models derived from patient cells to help personalize therapy for individuals with gastrointestinal cancers.

Bioengineered human livers mimic natural development

June 14, 2017
An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes - greatly advancing efforts to ...

Lab grown human colons change study of GI disease

June 22, 2017
Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem ...

Modular approach found to improve consistency of organoids

August 15, 2017
(Medical Xpress)—A team of researchers from the U.S. and Australia working at the Yale Stem Cell Center report that they have met with some success in improving the usefulness of organoids. In their paper published in the ...

Hairy skin grown from mouse stem cells

January 2, 2018
Indiana University School of Medicine researchers have cultured the first lab-grown skin tissue complete with hair follicles. This skin model, developed using stem cells from mice, more closely resembles natural hair than ...

Recommended for you

New era for blood transfusions through genome sequencing

May 18, 2018
Most people are familiar with A, B, AB and O blood types, but there are hundreds of additional blood group "antigens" on red blood cells—substances that can trigger the body's immune response—that differ from person to ...

Robots grow mini-organs from human stem cells

May 17, 2018
An automated system that uses robots has been designed to rapidly produce human mini-organs derived from stem cells. Researchers at the University of Washington School of Medicine in Seattle developed the new system.

Scientists uncover a new face of a famous protein, SWI2/SNF2 ATPase

May 17, 2018
A team of Texas A&M and Texas A&M AgriLife Research scientists now have a deeper understanding of a large switch/sucrose non-fermentable (SWI/SNF) protein complex that plays a pivotal role in plant and human gene expression ...

Antibacterial in your toothpaste may combat severe lung disease

May 17, 2018
A common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis, or CF, when combined with an already FDA-approved drug.

Emergency contact information helps researchers branch out family tree

May 17, 2018
When you go to the doctor or hospital, one piece of information that you're always asked to provide—in addition to your name, address, and insurance information—is an emergency contact. Often, that person is a blood relative. ...

Blocking two enzymes could make cancer cells mortal

May 17, 2018
EPFL scientists have identified two enzymes that protect chromosomes from oxidative damage and shortening. Blocking them might be a new anticancer strategy for stopping telomerase, the enzyme that immortalizes tumors.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.